Linked Life Data

11284724

Source:http://linkedlifedata.com/resource/pubmed/id/11284724

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11284724rdf:typepubmed:Citationlld:pubmed
pubmed-article:11284724lifeskim:mentionsumls-concept:C0057223lld:lifeskim
pubmed-article:11284724lifeskim:mentionsumls-concept:C1264638lld:lifeskim
pubmed-article:11284724lifeskim:mentionsumls-concept:C0243102lld:lifeskim
pubmed-article:11284724lifeskim:mentionsumls-concept:C1706204lld:lifeskim
pubmed-article:11284724lifeskim:mentionsumls-concept:C1555721lld:lifeskim
pubmed-article:11284724pubmed:issuePt 2lld:pubmed
pubmed-article:11284724pubmed:dateCreated2001-4-4lld:pubmed
pubmed-article:11284724pubmed:abstractTextHomology models of the active site of cytochrome P450 2D6 (CYP2D6) have identified phenylalanine 481 (Phe(481)) as a putative ligand-binding residue, its aromatic side chain being potentially capable of participating in pi-pi interactions with the benzene ring of ligands. We have tested this hypothesis by replacing Phe(481) with tyrosine (Phe(481)-->Tyr), a conservative substitution, and with leucine (Phe(481)-->Leu) or glycine (Phe(481)-->Gly), two non-aromatic residues, and have compared the properties of the wild-type and mutant enzymes in microsomes prepared from yeast cells expressing the appropriate cDNA-derived protein. The Phe(481)-->Tyr substitution did not alter the kinetics [K(m) (microM) and V(max) (pmol/min per pmol) respectively] of oxidation of S-metoprolol (27; 4.60), debrisoquine (46; 2.46) or dextromethorphan (2; 8.43) relative to the respective wild-type values [S-metoprolol (26; 3.48), debrisoquine (51; 3.20) and dextromethorphan (2; 8.16)]. The binding capacities [K(s) (microM)] of a range of CYP2D6 ligands to the Phe(481)-->Tyr enzyme (S-metoprolol, 22.8; debrisoquine, 12.5; dextromethorphan, 2.3; quinidine, 0.13) were also similar to those for the wild-type enzyme (S-metoprolol, 10.9; debrisoquine, 8.9; dextromethorphan, 3.1; quinidine, 0.10). In contrast, the Phe(481)-->Leu and Phe(481)-->Gly substitutions increased significantly (3-16-fold) the K(m) values of oxidation of the three substrates [S-metoprolol (120-124 microM), debrisoquine (152-184 microM) and dextromethorphan (20-31 microM)]. Similarly, the K(s) values of the ligands to Phe(481)-->Leu and Phe(481)-->Gly mutants were also increased 3 to 10-fold (S-metoprolol, 33.2-41.9 microM; debrisoquine, 85-90 microM; dextromethorphan, 15.7-18.8 microM; quinidine 0.35-0.53 microM). However, contrary to a recent proposal that Phe(481) has the dominant role in the binding of substrates that undergo CYP2D6-mediated N-dealkylation routes of metabolism, the Phe(481)-->Gly substitution did not substantially decrease the capacity of the enzyme to N-deisopropylate metoprolol (wild-type, 1.12 pmol/min per pmol of P450; Phe(481)-->Gly, 0.71), whereas an Asp(301)-->Gly substitution decreased the N-dealkylation reaction by 95% of the wild-type rate. Overall, our results are consistent with the proposal that Phe(481) is a ligand-binding residue in the active site of CYP2D6 and that the residue interacts with ligands via a pi-pi interaction between its phenyl ring and the aromatic moiety of the ligand. However, the relative importance of Phe(481) in binding is ligand-dependent; furthermore, its importance is secondary to that of Asp(301). Finally, contrary to predictions of a recent homology model, Phe(481) does not seem to have a primary role in CYP2D6-mediated N-dealkylation.lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:languageenglld:pubmed
pubmed-article:11284724pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:citationSubsetIMlld:pubmed
pubmed-article:11284724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11284724pubmed:statusMEDLINElld:pubmed
pubmed-article:11284724pubmed:monthAprlld:pubmed
pubmed-article:11284724pubmed:issn0264-6021lld:pubmed
pubmed-article:11284724pubmed:authorpubmed-author:TuckerG TGTlld:pubmed
pubmed-article:11284724pubmed:authorpubmed-author:GrossEElld:pubmed
pubmed-article:11284724pubmed:authorpubmed-author:LennardM SMSlld:pubmed
pubmed-article:11284724pubmed:authorpubmed-author:FLOOGDDlld:pubmed
pubmed-article:11284724pubmed:authorpubmed-author:HarlowJJlld:pubmed
pubmed-article:11284724pubmed:authorpubmed-author:HiltonEElld:pubmed
pubmed-article:11284724pubmed:authorpubmed-author:HayhurstG PGPlld:pubmed
pubmed-article:11284724pubmed:authorpubmed-author:ChowdryJJlld:pubmed
pubmed-article:11284724pubmed:issnTypePrintlld:pubmed
pubmed-article:11284724pubmed:day15lld:pubmed
pubmed-article:11284724pubmed:volume355lld:pubmed
pubmed-article:11284724pubmed:ownerNLMlld:pubmed
pubmed-article:11284724pubmed:authorsCompleteYlld:pubmed
pubmed-article:11284724pubmed:pagination373-9lld:pubmed
pubmed-article:11284724pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:11284724pubmed:meshHeadingpubmed-meshheading:11284724...lld:pubmed
pubmed-article:11284724pubmed:meshHeadingpubmed-meshheading:11284724...lld:pubmed
pubmed-article:11284724pubmed:meshHeadingpubmed-meshheading:11284724...lld:pubmed
pubmed-article:11284724pubmed:meshHeadingpubmed-meshheading:11284724...lld:pubmed
pubmed-article:11284724pubmed:meshHeadingpubmed-meshheading:11284724...lld:pubmed
pubmed-article:11284724pubmed:meshHeadingpubmed-meshheading:11284724...lld:pubmed
pubmed-article:11284724pubmed:meshHeadingpubmed-meshheading:11284724...lld:pubmed
pubmed-article:11284724pubmed:meshHeadingpubmed-meshheading:11284724...lld:pubmed
pubmed-article:11284724pubmed:meshHeadingpubmed-meshheading:11284724...lld:pubmed
pubmed-article:11284724pubmed:meshHeadingpubmed-meshheading:11284724...lld:pubmed
pubmed-article:11284724pubmed:meshHeadingpubmed-meshheading:11284724...lld:pubmed
pubmed-article:11284724pubmed:year2001lld:pubmed
pubmed-article:11284724pubmed:articleTitleInfluence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.lld:pubmed
pubmed-article:11284724pubmed:affiliationUniversity of Sheffield, Molecular Pharmacology and Pharmacogenetics, Division of Clinical Sciences, Royal Hallamshire Hospital, Sheffield S10 2JF, UK.lld:pubmed
pubmed-article:11284724pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11284724pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11284724lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11284724lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11284724lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11284724lld:pubmed